TCRX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
TCRX is not a good buy right now for an impatient investor. The trend is clearly bearish (moving averages stacked bearishly and MACD weakening), there are no Intellectia buy signals today, and Wall Street sentiment has deteriorated due to program delays and fewer near-term catalysts. With downside-biased pattern odds over the next month, the risk/reward is unfavorable for an immediate entry.
Price/Trend: Bearish trend with SMA_200 > SMA_20 > SMA_5 (persistent downtrend). Momentum: MACD histogram -0.0138 and negatively expanding, signaling bearish momentum is strengthening. RSI_6 at 22.275 indicates the stock is very weak/near oversold conditions (possible short-term bounce risk), but oversold alone is not a buy signal here given the broader downtrend. Levels: Pivot 1.104 is overhead (current post-market ~1.04), implying the stock is below a key pivot. Immediate support S1 1.026 then S2 0.978; resistance R1 1.183 then R2 1.231. Quant/Pattern read-through: Similar-pattern stats imply a likely -8.55% over the next month, reinforcing the bearish setup.
Intellectia Proprietary Trading Signals
Hedge funds are buying (reported buying amount up 12447.81% QoQ), which can provide incremental support. Very weak/near-oversold RSI can allow for sharp short-term rebounds. Latest quarter showed strong YoY revenue growth (though from a low base).
Analyst downgrades and lower price targets tied to delayed catalysts: pivotal TSC-101 study initiation pushed to Q2 FY26 and solid-tumor program paused, reducing near-term upside drivers. No news/catalysts in the past week. Technicals remain decisively bearish (downtrend + deteriorating MACD). Pattern-based expectation suggests negative 1-month performance (-8.55%).
Latest quarter: 2025/Q3. Revenue increased to $2.511M (+139.37% YoY), but profitability remains deeply negative: net income -$35.71M (loss improved 19.48% YoY) and EPS -0.28 (improved 12% YoY). Gross margin listed at 100 (flat YoY), consistent with the company still being in a development-stage profile where operating expenses drive losses. Overall: improving YoY trends, but still cash-burn/early-stage dynamics with limited near-term fundamental inflection indicated in the data provided.
Recent trend: ratings and targets moved down materially. Morgan Stanley downgraded to Equal Weight from Overweight and cut its base-case target range to $1-$5 (from $7-$13) due to reduced visibility and trial timing pushed out to Q2 FY26. BTIG downgraded to Neutral from Buy after the company prioritized hematologic malignancy and paused solid-tumor enrollment, citing fewer near-term catalysts and a later assumed approval timeline. Needham maintained Buy but reduced its target to $6 from $9, noting ASH abstract data suggesting some loss of activity vs. prior year. Wall Street pros: TSC-101 still seen as potentially meaningful in a high-need setting. Wall Street cons: delayed pivotal timeline, program narrowing, less catalyst density, and reduced confidence/visibility—net negative near-term.
